TABLE OF CONTENTS
1 INTRODUCTION 53
1.1 OBJECTIVES OF THE STUDY 53
1.2 MARKET DEFINITION 53
1.3 OVERVIEW OF THE NORTH AMERICA EXOSOME RESEARCH PRODUCTS MARKET 53
1.4 LIMITATIONS 55
1.5 MARKETS COVERED 55
2 MARKET SEGMENTATION 58
2.1 MARKETS COVERED 58
2.2 GEOGRAPHICAL SCOPE 59
2.3 YEARS CONSIDERED FOR THE STUDY 60
2.4 CURRENCY AND PRICING 60
2.5 DBMR TRIPOD DATA VALIDATION MODEL 61
2.6 MULTIVARIATE MODELLING 64
2.7 PRODUCT LIFELINE CURVE 65
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.9 DBMR MARKET POSITION GRID 67
2.10 MARKET APPLICATION COVERAGE GRID 69
2.11 VENDOR SHARE ANALYSIS 70
2.12 SECONDARY SOURCES 71
2.13 ASSUMPTIONS 71
3 EXECUTIVE SUMMARY 72
4 PREMIUM INSIGHTS 74
4.1 PESTEL ANALYSIS 75
4.2 PORTER'S FIVE FORCES MODEL 76
4.3 SUPPLY CHAIN ANALYSIS 77
4.4 VALUE CHAIN ANALYSIS 78
4.5 BUSINESS STRATEGY EXCELLENCE 79
4.6 CASE STUDIES 80
4.7 STRENGTH OF PRODUCT PORTFOLIO 82
4.8 TECHNOLOGICAL TRENDS 84
4.9 PRICING ANALYSIS 85
5 INDUSTRY INSIGHTS 86
6 NORTH AMERICA EXOSOME RESEARCH PRODUCTS MARKET, REGULATIONS 87
7 MARKET OVERVIEW 89
7.1 DRIVERS 91
7.1.1 GROWING PREVALENCE OF CANCER, CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE, LYME DISEASE, AND OTHER CHRONIC DEGENERATIVE DISEASES 91
7.1.2 INCREASING INVESTMENTS IN PHARMACEUTICAL R&D AND LIFE SCIENCES RESEARCH 91
7.1.3 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES AND PROGRESSING THERAPEUTIC VALUE OF EXOSOME 92
7.2 RESTRAINTS 93
7.2.1 LACK OF GOLD STANDARD PROTOCOLS FOR THE DEVELOPMENT AND PRODUCTION OF EXOSOMES 93
7.2.2 THE SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE ISOLATION OF EXOSOME 93
7.3 OPPORTUNITIES 94
7.3.1 RISING DEMAND FOR SPECIALIZED TESTING SERVICES AMONG END USERS. 94
7.3.2 INCREASING ADVANCEMENT IN EXOSOME TECHNOLOGY 94
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 95
7.4 CHALLENGES 96
7.4.1 SIDE EFFECTS ASSOCIATED WITH EXOSOME RESEARCH PRODUCTS 96
7.4.2 LATE APPROVAL ASSOCIATED WITH PRODUCT LAUNCHES 96
8 NORTH AMERICA EXOSOME RESEARCH PRODUCTS MARKET, BY PRODUCT 97
8.1 OVERVIEW 98
8.2 CONSUMABLES 101
8.2.1 KITS AND REAGENTS 102
8.2.1.1 EXOSOME BIOMARKER KITS 103
8.2.1.2 EXOSOME ISOLATION KITS 103
8.2.1.3 EXOSOME PURIFICATION KITS 103
8.2.1.4 EXOSOME QUANTITATIVE KITS 103
8.2.1.5 EXOSOME DETECTION KITS 103
8.2.1.6 OTHERS 103
8.2.2 EXOSOME STANDARDS 103
8.2.3 EXOSOME ANTIBODIES 103
8.2.4 CELL LINES 103
8.2.5 IMMUNOPLATES 104
8.2.6 IMMUNOBEADS 104
8.2.7 BIOFLUIDS 104
8.2.8 OTHERS 104
8.3 INSTRUMENTS 104
8.3.1 BENCHTOP 105
8.3.2 STANDALONE 105
9 NORTH AMERICA EXOSOME RESEARCH PRODUCTS MARKET, BY INDICATION 106
9.1 OVERVIEW 107
9.2 CANCER 110
9.2.1 LUNG CANCER 111
9.2.2 BREAST CANCER 111
9.2.3 COLORECTAL CANCER 111
9.2.4 PROSTATE CANCER 112
9.2.5 OTHER CANCER 112
9.3 NON-CANCER 112
9.3.1 CARDIOVASCULAR DISEASE 113
9.3.2 NEURODEGENERATIVE DISEASE 113
9.3.3 INFECTIOUS DISEASE 113
9.3.4 OTHERS 113
10 NORTH AMERICA EXOSOME RESEARCH PRODUCTS MARKET: BY APPLICATION 114
10.1 OVERVIEW 115
10.2 THERAPEUTICS 118
10.3 CONSUMABLES 119
10.4 INSTRUMENTS 119
10.5 DIAGNOSIS 119
10.6 CONSUMABLES 120
10.7 INSTRUMENTS 120
11 NORTH AMERICA EXOSOME RESEARCH PRODUCTS MARKET, BY END USER 121
11.1 OVERVIEW 122
11.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANY 125
11.3 CONSUMABLES 126
11.4 INSTRUMENTS 126
11.5 RESEARCH CENTRES 126
11.6 CONSUMABLES 127
11.7 INSTRUMENTS 127
11.8 ACADEMIC INSTITUTES 127
11.9 CONSUMABLES 128
11.10 INSTRUMENTS 128
11.11 CLINICAL TESTING LABORATORY 128
11.12 CONSUMABLES 129
11.13 INSTRUMENTS 129
11.14 HOSPITALS 130
11.15 CONSUMABLES 131
11.16 INSTRUMENTS 131
11.17 OTHERS 131
12 NORTH AMERICA EXOSOME RESEARCH PRODUCTS MARKET, BY DISTRIBUTION CHANNEL 132
12.1 OVERVIEW 133
12.2 THIRD PARTY DISTRIBUTORS 136
12.3 DIRECT SALES 136
12.4 ONLINE 137
13 NORTH AMERICA EXOSOME RESEARCH PRODUCTS MARKET, BY REGION 138
13.1 NORTH AMERICA 139
13.1.1 U.S. 149
13.1.2 CANADA 155
13.1.3 MEXICO 161
14 NORTH AMERICA EXOSOME RESEARCH PRODUCTS MARKET, COMPANY LANDSCAPE 167
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 167
15 SWOT ANALYSIS 168
16 COMPANY PROFILE 169
16.1 THERMO FISHER SCIENTIFIC INC. 169
16.1.1 COMPANY SNAPSHOT 169
16.1.2 REVENUE ANALYSIS 169
16.1.3 COMPANY SHARE ANALYSIS 170
16.1.4 PRODUCT PORTFOLIO 170
16.1.5 RECENT DEVELOPMENT 171
16.2 EXODX (ACQUIRED BY BIO-TECHNE) 172
16.2.1 COMPANY SNAPSHOT 172
16.2.2 REVENUE ANALYSIS 172
16.2.3 COMPANY SHARE ANALYSIS 173
16.2.4 PRODUCT PORTFOLIO 173
16.2.5 RECENT DEVELOPMENT 173
16.3 MILTENYI BIOTEC 174
16.3.1 COMPANY SNAPSHOT 174
16.3.2 COMPANY SHARE ANALYSIS 174
16.3.3 PRODUCT PORTFOLIO 175
16.3.4 RECENT DEVELOPMENTS 175
16.4 LUMINEX CORPORATION 176
16.4.1 COMPANY SNAPSHOT 176
16.4.2 PRODUCT PORTFOLIO 176
16.4.3 RECENT DEVELOPMENT 176
16.5 HOLOGIC, INC. 177
16.5.1 COMPANY SNAPSHOT 177
16.5.2 REVENUE ANALYSIS 177
16.5.3 COMPANY SHARE ANALYSIS 178
16.5.4 PRODUCT PORTFOLIO 178
16.5.5 RECENT DEVELOPMENTS 178
16.6 AETHLON MEDICAL, INC. (2022) 179
16.6.1 COMPANY SNAPSHOT 179
16.6.2 PRODUCT PORTFOLIO 180
16.6.3 RECENT DEVELOPMENTS 180
16.7 AGILENT TECHNOLOGIES, INC. 181
16.7.1 COMPANY SNAPSHOT 181
16.7.2 REVENUE ANALYSIS 181
16.7.3 PRODUCT PORTFOLIO 182
16.7.4 RECENT DEVELOPMENT 182
16.8 AMSBI0 183
16.8.1 COMPANY SNAPSHOT 183
16.8.2 PRODUCT PORTFOLIO 183
16.8.3 RECENT DEVELOPMENT 183
16.9 AUDUBON BIOSCIENCE. 184
16.9.1 COMPANY SNAPSHOT 184
16.9.2 PRODUCT PORTFOLIO 184
16.9.3 RECENT DEVELOPMENT 184
16.10 BECKMAN COULTER, INC 185
16.10.1 COMPANY SNAPSHOT 185
16.10.2 PRODUCT PORTFOLIO 185
16.10.3 RECENT DEVELOPMENT 185
16.11 BIOVISION INC. (ACQUIRED BY ABCAM PLC) 186
16.11.1 COMPANY SNAPSHOT 186
16.11.2 REVENUE ANALYSIS 186
16.11.3 COMPANY SHARE ANALYSIS 187
16.11.4 PRODUCT PORTFOLIO 187
16.11.5 RECENT DEVELOPMENT 187
16.12 CELL GUIDANCE SYSTEMS LLC 188
16.12.1 COMPANY SNAPSHOT 188
16.12.2 PRODUCT PORTFOLIO 188
16.12.3 RECENT DEVELOPMENTS 188
16.13 CREATIVE BIOARRAY 189
16.13.1 COMPANY SNAPSHOT 189
16.13.2 PRODUCT PORTFOLIO 189
16.13.3 RECENT DEVELOPMENT 189
16.14 CUSABIO TECHNOLOGY LLC 190
16.14.1 COMPANY SNAPSHOT 190
16.14.2 PRODUCT PORTFOLIO 190
16.14.3 RECENT DEVELOPMENTS 190
16.15 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION 191
16.15.1 COMPANY SNAPSHOT 191
16.15.2 REVENUE ANALYSIS 191
16.15.3 PRODUCT PORTFOLIO 192
16.15.4 RECENT DEVELOPMENT 192
16.16 HBMLS (ACQUIRED BY LONZA) 193
16.16.1 COMPANY SNAPSHOT 193
16.16.2 REVENUE ANALYSIS 193
16.16.3 PRODUCT PORTFOLIO 194
16.16.4 RECENT DEVELOPMENT 194
16.17 HITACHI, LTD. 195
16.17.1 COMPANY SNAPSHOT 195
16.17.2 REVENUE ANALYSIS 195
16.17.3 PRODUCT PORTFOLIO 196
16.17.4 RECENT DEVELOPMENT 196
16.18 INOVIQ 197
16.18.1 COMPANY SNAPSHOT 197
16.18.2 REVENUE ANALYSIS 197
16.18.3 PRODUCT PORTFOLIO 198
16.18.4 RECENT DEVELOPMENT 198
16.19 JSR MICRO NV 199
16.19.1 COMPANY SNAPSHOT 199
16.19.2 PRODUCT PORTFOLIO 199
16.19.3 RECENT DEVELOPMENT 199
16.20 MICROGENTAS 200
16.20.1 COMPANY SNAPSHOT 200
16.20.2 PRODUCT PORTFOLIO 200
16.20.3 RECENT DEVELOPMENTS 200
16.21 NANOSOMIX 201
16.21.1 COMPANY SNAPSHOT 201
16.21.2 PRODUCT PORTFOLIO 201
16.21.3 RECENT DEVELOPMENT 201
16.22 NEXOSOME-ONCOLOGY 202
16.22.1 COMPANY SNAPSHOT 202
16.22.2 PRODUCT PORTFOLIO 202
16.22.3 RECENT DEVELOPMENTS 202
16.23 NORGEN BIOTEK CORP. 203
16.23.1 COMPANY SNAPSHOT 203
16.23.2 PRODUCT PORTFOLIO 203
16.23.3 RECENT DEVELOPMENTS 203
16.24 NOVUS BIOLOGICALS 204
16.24.1 COMPANY SNAPSHOT 204
16.24.2 PRODUCT PORTFOLIO 204
16.24.3 RECENT DEVELOPMENT 205
16.25 PROTEOGENEX 206
16.25.1 COMPANY SNAPSHOT 206
16.25.2 PRODUCT PORTFOLIO 206
16.25.3 RECENT DEVELOPMENT 206
16.26 QIAGEN 207
16.26.1 COMPANY SNAPSHOT 207
16.26.2 REVENUE ANALYSIS 207
16.26.3 PRODUCT PORTFOLIO 208
16.26.4 RECENT DEVELOPMENT 208
16.27 ROOSTERBIO, INC. 209
16.27.1 COMPANY SNAPSHOT 209
16.27.2 PRODUCT PORTFOLIO 209
16.27.3 RECENT DEVELOPMENTS 210
16.28 SYSTEM BIOSCIENCES, LLC. 211
16.28.1 COMPANY SNAPSHOT 211
16.28.2 PRODUCT PORTFOLIO 211
16.28.3 RECENT DEVELOPMENT 211
17 QUESTIONNAIRE 212

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.